In the BioHarmony Drug Report Database

"Preview" Icon

Riluzole

Exservan, Rilutek, Tiglutik, Riluzole Zentiva (riluzole) is a small molecule pharmaceutical. Riluzole was first approved as Exservan on 1995-12-12. It is used to treat amyotrophic lateral sclerosis in the USA. It has been approved in Europe to treat amyotrophic lateral sclerosis. It is known to target potassium channel subfamily K member 4, intermediate conductance calcium-activated potassium channel protein 4, potassium channel subfamily K member 2, potassium voltage-gated channel subfamily H member 2, short transient receptor potential channel 5, small conductance calcium-activated potassium channel protein 3, potassium voltage-gated channel subfamily D member 2, small conductance calcium-activated potassium channel protein 1, small conductance calcium-activated potassium channel protein 2, potassium voltage-gated channel subfamily D member 3, and calmodulin-1. Riluzole’s patents are valid until 2029-03-12 (FDA).

 

Trade Name

 

Rilutek, Riluzole Zentiva
 

Common Name

 

riluzole
 

ChEMBL ID

 

CHEMBL744
 

Indication

 

amyotrophic lateral sclerosis
 

Drug Class

 

Image (chem structure or protein)

Riluzole structure rendering